News

The new grant will support the completion of a Phase IIa trial of MN-166 in opioid dependence, for which the company had recently released positive interim results. The

The approval was based on data from a Phase III registration program, which showed that ferric citrate reduced serum phosphorus levels to well within the KDOQI guidelines range

The indication of Keytruda 2mg/kg every three weeks is approved under accelerated approval based on tumor response rate and durability of response. Keytruda, the first anti-programmed death receptor-1

As part of the deal, Navidea will earn royalties on units sales, an upfront payment of $300,000, up to $700,000 in development milestone payments and up to $1.5m

The Public Health Agency of Canada (PHAC) has initially developed the vaccine, which is under an exclusive licensing arrangement with BioProtection Systems, a subsidiary of NewLink Genetics. The

The University and biOasis continue to develop biOasis’ extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier

A therapeutically aligned infectious diseases team will support all ID studies at PSI, focused to provide optimized approaches to patient enrollment. The team will include staff from various

The acquisition reflects the organization’s recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space. The real estate

The results of this Phase 2 study, investigating the efficacy and safety of this topical ACT1 formulation when combined with standard care in treatment of chronic venous leg